DE50214200D1
(de)
|
2001-06-05 |
2010-03-25 |
Curevac Gmbh |
Stabilisierte Tumorantigen-mRNA mit erhöhtem G/C-Gehalt
|
DE10162480A1
(de)
|
2001-12-19 |
2003-08-07 |
Ingmar Hoerr |
Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
|
DE10347710B4
(de)
|
2003-10-14 |
2006-03-30 |
Johannes-Gutenberg-Universität Mainz |
Rekombinante Impfstoffe und deren Verwendung
|
US9012219B2
(en)
*
|
2005-08-23 |
2015-04-21 |
The Trustees Of The University Of Pennsylvania |
RNA preparations comprising purified modified RNA for reprogramming cells
|
ES2735531T3
(es)
|
2005-08-23 |
2019-12-19 |
Univ Pennsylvania |
ARN que contiene nucleósidos modificados y métodos de uso del mismo
|
US20070054873A1
(en)
*
|
2005-08-26 |
2007-03-08 |
Protiva Biotherapeutics, Inc. |
Glucocorticoid modulation of nucleic acid-mediated immune stimulation
|
DE102005046490A1
(de)
|
2005-09-28 |
2007-03-29 |
Johannes-Gutenberg-Universität Mainz |
Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
|
WO2007051303A1
(en)
|
2005-11-02 |
2007-05-10 |
Protiva Biotherapeutics, Inc. |
MODIFIED siRNA MOLECULES AND USES THEREOF
|
US7915399B2
(en)
*
|
2006-06-09 |
2011-03-29 |
Protiva Biotherapeutics, Inc. |
Modified siRNA molecules and uses thereof
|
JP5876637B2
(ja)
*
|
2006-10-18 |
2016-03-02 |
マリーナ バイオテック,インコーポレイテッド |
ニックまたはギャップの入った核酸分子およびそれらの使用
|
DE102006051516A1
(de)
*
|
2006-10-31 |
2008-05-08 |
Curevac Gmbh |
(Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins
|
DE102007001370A1
(de)
*
|
2007-01-09 |
2008-07-10 |
Curevac Gmbh |
RNA-kodierte Antikörper
|
EP2121924A1
(en)
*
|
2007-03-02 |
2009-11-25 |
MDRNA, Inc. |
Nucleic acid compounds for inhibiting vegf family gene expression and uses thereof
|
JP2010519912A
(ja)
*
|
2007-03-02 |
2010-06-10 |
エムディーアールエヌエー,インコーポレイテッド |
Ras遺伝子の発現を抑制するための核酸化合物およびその使用
|
US20100112687A1
(en)
*
|
2007-03-02 |
2010-05-06 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting erbb family gene expression and uses thereof
|
WO2009046739A1
(en)
*
|
2007-10-09 |
2009-04-16 |
Curevac Gmbh |
Composition for treating prostate cancer (pca)
|
WO2009127230A1
(en)
*
|
2008-04-16 |
2009-10-22 |
Curevac Gmbh |
MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
|
WO2010088927A1
(en)
*
|
2009-02-09 |
2010-08-12 |
Curevac Gmbh |
Use of pei for the improvement of endosomal release and expression of transfected nucleic acids, complexed with cationic or polycationic compounds
|
WO2010123501A1
(en)
*
|
2009-04-22 |
2010-10-28 |
Massachusetts Institute Of Technology |
Innate immune suppression enables repeated delivery of long rna molecules
|
US10837020B2
(en)
|
2009-04-22 |
2020-11-17 |
Massachusetts Institute Of Technology |
Innate immune suppression enables repeated delivery of long RNA molecules
|
CA2766907A1
(en)
|
2009-07-06 |
2011-01-13 |
Novartis Ag |
Self replicating rna molecules and uses thereof
|
DK2459231T3
(en)
*
|
2009-07-31 |
2016-09-05 |
Ethris Gmbh |
RNA with a combination of unmodified and modified nucleotides for protein expression
|
DE102009050308A1
(de)
|
2009-10-22 |
2011-05-05 |
Ludwig-Maximilians-Universität München |
RNA mit einer Kombination aus unmodifizierten und modifizierten Nucleotiden zur Proteinexpression
|
WO2011026185A1
(en)
*
|
2009-09-04 |
2011-03-10 |
Murdoch Childrens Research Institute |
An assay for monitoring a neurological condition
|
NZ700688A
(en)
|
2009-12-01 |
2016-02-26 |
Shire Human Genetic Therapies |
Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
|
EP3623474A1
(en)
|
2009-12-07 |
2020-03-18 |
The Trustees of The University of Pennsylvania |
Rna preparations comprising purified modified rna for reprogramming cells
|
AU2015215938B2
(en)
*
|
2009-12-07 |
2018-01-18 |
The Trustees Of The University Of Pennsylvania |
RNA preparations comprising purified modified RNA for reprogramming cells
|
EP2338520A1
(de)
|
2009-12-21 |
2011-06-29 |
Ludwig Maximilians Universität |
Konjugat mit Zielfindungsligand und dessen Verwendung
|
CA2796464C
(en)
|
2010-04-16 |
2021-08-03 |
Immune Disease Institute, Inc. |
Sustained polypeptide expression from synthetic, modified rnas and uses thereof
|
WO2012006369A2
(en)
|
2010-07-06 |
2012-01-12 |
Novartis Ag |
Immunisation of large mammals with low doses of rna
|
DK3243526T3
(da)
|
2010-07-06 |
2020-02-17 |
Glaxosmithkline Biologicals Sa |
Levering af rna til at udløse flere immunsignalveje
|
EP2590626B1
(en)
|
2010-07-06 |
2015-10-28 |
GlaxoSmithKline Biologicals SA |
Liposomes with lipids having an advantageous pka-value for rna delivery
|
RS63817B1
(sr)
|
2010-07-06 |
2023-01-31 |
Glaxosmithkline Biologicals Sa |
Čestice za isporuku slične virionu za molekule samoreplicirajuće rnk
|
US8822663B2
(en)
|
2010-08-06 |
2014-09-02 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
WO2012019630A1
(en)
|
2010-08-13 |
2012-02-16 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
|
EP4119155A1
(en)
|
2010-08-31 |
2023-01-18 |
GlaxoSmithKline Biologicals S.A. |
Pegylated liposomes for delivery of immunogen-encoding rna
|
HUE058896T2
(hu)
*
|
2010-10-01 |
2022-09-28 |
Modernatx Inc |
N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai
|
TR201903651T4
(tr)
|
2010-10-11 |
2019-04-22 |
Glaxosmithkline Biologicals Sa |
Antijen uygulama platformları.
|
US8853377B2
(en)
|
2010-11-30 |
2014-10-07 |
Shire Human Genetic Therapies, Inc. |
mRNA for use in treatment of human genetic diseases
|
US8710200B2
(en)
*
|
2011-03-31 |
2014-04-29 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids encoding a modified erythropoietin and their expression
|
EP3460064B8
(en)
*
|
2011-04-03 |
2024-03-20 |
The General Hospital Corporation d/b/a Massachusetts General Hospital |
Efficient protein expression in vivo using modified rna (mod-rna)
|
CN103687957A
(zh)
*
|
2011-05-17 |
2014-03-26 |
现代治疗公司 |
工程化核酸及其用于非人类脊椎动物的方法
|
SI3892295T1
(sl)
|
2011-05-24 |
2023-09-29 |
BioNTech SE |
Individualizirana cepiva proti raku
|
JP6184945B2
(ja)
|
2011-06-08 |
2017-08-23 |
シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド |
mRNA送達のための脂質ナノ粒子組成物および方法
|
CA2840989A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic combination compositions and uses thereof
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
RS62993B1
(sr)
|
2011-10-03 |
2022-03-31 |
Modernatx Inc |
Modifikovani nukleozidi, nukleotidi, i nukleinske kiseline, i njihove upotrebe
|
WO2013078199A2
(en)
*
|
2011-11-23 |
2013-05-30 |
Children's Medical Center Corporation |
Methods for enhanced in vivo delivery of synthetic, modified rnas
|
US8497124B2
(en)
|
2011-12-05 |
2013-07-30 |
Factor Bioscience Inc. |
Methods and products for reprogramming cells to a less differentiated state
|
RU2691027C2
(ru)
*
|
2011-12-05 |
2019-06-07 |
Фэктор Байосайенс Инк. |
Способы и препараты для трансфекции клеток
|
ES2921724T1
(es)
|
2011-12-07 |
2022-08-31 |
Alnylam Pharmaceuticals Inc |
Lípidos biodegradables para la administración de agentes activos
|
CN104114572A
(zh)
|
2011-12-16 |
2014-10-22 |
现代治疗公司 |
经修饰的核苷、核苷酸和核酸组合物
|
CA2859691A1
(en)
*
|
2011-12-21 |
2013-06-27 |
Moderna Therapeutics, Inc. |
Methods of increasing the viability or longevity of an organ or organ explant
|
EP4372081A2
(en)
|
2011-12-30 |
2024-05-22 |
Cellscript, Llc |
Making and using in vitro-synthesized ssrna for introducing into mammalian cells to induce a biological or biochemical effect
|
WO2013120499A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
|
WO2013120500A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
|
WO2013120498A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
|
WO2013120497A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
|
WO2013143555A1
(en)
|
2012-03-26 |
2013-10-03 |
Biontech Ag |
Rna formulation for immunotherapy
|
MX358706B
(es)
*
|
2012-03-27 |
2018-08-31 |
Curevac Ag |
Moleculas de acido nucleico artificiales que comprenden un top 5´utr.
|
DK3578659T3
(da)
|
2012-03-27 |
2024-02-05 |
CureVac SE |
Kunstige nukelinsyremolekyler til forbedret protein- eller peptidekspression
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
US9303079B2
(en)
|
2012-04-02 |
2016-04-05 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
JP2015518705A
(ja)
*
|
2012-04-02 |
2015-07-06 |
モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. |
ヒト疾患に関連する生物製剤およびタンパク質の産生のための修飾ポリヌクレオチド
|
US10501513B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides for the production of oncology-related proteins and peptides
|
DE18200782T1
(de)
|
2012-04-02 |
2021-10-21 |
Modernatx, Inc. |
Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
|
EP3597741A1
(en)
|
2012-04-27 |
2020-01-22 |
Duke University |
Genetic correction of mutated genes
|
EP3553086A1
(en)
|
2012-05-31 |
2019-10-16 |
Sorrento Therapeutics Inc. |
Antigen binding proteins that bind pd-l1
|
BR112014029807A2
(pt)
*
|
2012-06-08 |
2017-06-27 |
Ethris Gmbh |
administração pulmonar de rna mensageiro
|
EA201492055A1
(ru)
|
2012-06-08 |
2015-11-30 |
Шир Хьюман Дженетик Терапис, Инк. |
ИНГАЛЯЦИОННАЯ ДОСТАВКА мРНК В НЕЛЕГОЧНЫЕ КЛЕТКИ-МИШЕНИ
|
EP3536787A1
(en)
|
2012-06-08 |
2019-09-11 |
Translate Bio, Inc. |
Nuclease resistant polynucleotides and uses thereof
|
WO2014028429A2
(en)
|
2012-08-14 |
2014-02-20 |
Moderna Therapeutics, Inc. |
Enzymes and polymerases for the synthesis of rna
|
SG11201501681SA
(en)
|
2012-09-07 |
2015-04-29 |
Genentech Inc |
Methods and compositions for producing induced hepatocytes
|
JOP20200308A1
(ar)
|
2012-09-07 |
2017-06-16 |
Novartis Ag |
جزيئات إرتباط il-18
|
RU2711249C2
(ru)
|
2012-11-01 |
2020-01-15 |
Фэктор Байосайенс Инк. |
Способы и продукты для экспрессии белков в клетках
|
EP4074834A1
(en)
*
|
2012-11-26 |
2022-10-19 |
ModernaTX, Inc. |
Terminally modified rna
|
WO2014082729A1
(en)
|
2012-11-28 |
2014-06-05 |
Biontech Ag |
Individualized vaccines for cancer
|
EP2929035A1
(en)
*
|
2012-12-07 |
2015-10-14 |
Shire Human Genetic Therapies, Inc. |
Lipidic nanoparticles for mrna delivering
|
US20150315541A1
(en)
*
|
2012-12-13 |
2015-11-05 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for altering cell phenotype
|
JP2016504050A
(ja)
|
2013-01-17 |
2016-02-12 |
モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. |
細胞表現型の改変のためのシグナルセンサーポリヌクレオチド
|
SG11201505330QA
(en)
|
2013-02-08 |
2015-08-28 |
Novartis Ag |
Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
|
WO2015198217A2
(en)
|
2013-02-08 |
2015-12-30 |
Novartis Ag |
Compositions and methods for long-acting antibodies targeting il-17
|
IL296870A
(en)
|
2013-02-22 |
2022-11-01 |
Univ Leland Stanford Junior |
Nucleic acids encoding telomerase reverse transcriptase, preparations containing them and their uses
|
EP2968391A1
(en)
*
|
2013-03-13 |
2016-01-20 |
Moderna Therapeutics, Inc. |
Long-lived polynucleotide molecules
|
EA037922B1
(ru)
|
2013-03-14 |
2021-06-07 |
Шир Хьюман Дженетик Терапис, Инк. |
мРНК CFTR И КОМПОЗИЦИИ ДЛЯ ЛЕЧЕНИЯ МУКОВИСЦИДОЗА У МЛЕКОПИТАЮЩЕГО
|
EP2970955B1
(en)
|
2013-03-14 |
2018-11-14 |
Translate Bio, Inc. |
Methods for purification of messenger rna
|
US20160032316A1
(en)
|
2013-03-14 |
2016-02-04 |
The Trustees Of The University Of Pennsylvania |
Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides
|
WO2014160284A1
(en)
*
|
2013-03-14 |
2014-10-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of stroke
|
EP2971010B1
(en)
|
2013-03-14 |
2020-06-10 |
ModernaTX, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
EP2971165A4
(en)
|
2013-03-15 |
2016-11-23 |
Moderna Therapeutics Inc |
DISSOLUTION OF DNA FRAGMENTS IN MRNA MANUFACTURING METHODS
|
WO2014144767A1
(en)
|
2013-03-15 |
2014-09-18 |
Moderna Therapeutics, Inc. |
Ion exchange purification of mrna
|
US9957515B2
(en)
|
2013-03-15 |
2018-05-01 |
Cibus Us Llc |
Methods and compositions for targeted gene modification
|
WO2014152027A1
(en)
|
2013-03-15 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Manufacturing methods for production of rna transcripts
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
US11377470B2
(en)
|
2013-03-15 |
2022-07-05 |
Modernatx, Inc. |
Ribonucleic acid purification
|
DE102013005361A1
(de)
*
|
2013-03-28 |
2014-10-02 |
Eberhard Karls Universität Tübingen Medizinische Fakultät |
Polyribonucleotid
|
CN105518146B
(zh)
|
2013-04-04 |
2022-07-15 |
哈佛学院校长同事会 |
利用CRISPR/Cas系统的基因组编辑的治疗性用途
|
WO2014180490A1
(en)
|
2013-05-10 |
2014-11-13 |
Biontech Ag |
Predicting immunogenicity of t cell epitopes
|
JP6625521B2
(ja)
|
2013-05-15 |
2020-01-08 |
リボカイン,エルエルシー |
環状rnaの細胞内翻訳
|
CA2916800C
(en)
|
2013-06-28 |
2022-10-25 |
Ethris Gmbh |
Compositions comprising a component with oligo(alkylene amine) moieties
|
EP3971287A1
(en)
|
2013-07-11 |
2022-03-23 |
ModernaTX, Inc. |
Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use
|
KR102250027B1
(ko)
|
2013-07-26 |
2021-05-07 |
교토후고리츠다이가쿠호진 |
골아 세포 및 그 조제 방법
|
AU2014315287A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
EP3052106A4
(en)
|
2013-09-30 |
2017-07-19 |
ModernaTX, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
US10385088B2
(en)
|
2013-10-02 |
2019-08-20 |
Modernatx, Inc. |
Polynucleotide molecules and uses thereof
|
MX2016004249A
(es)
|
2013-10-03 |
2016-11-08 |
Moderna Therapeutics Inc |
Polinulcleotidos que codifican el receptor de lipoproteina de baja densidad.
|
DE102013111099B4
(de)
|
2013-10-08 |
2023-11-30 |
Eberhard Karls Universität Tübingen Medizinische Fakultät |
Permanente Genkorrektur mittels nukleotidmodifizierter messenger RNA
|
EP3060257B1
(en)
|
2013-10-22 |
2021-02-24 |
Translate Bio, Inc. |
Lipid formulations for delivery of messenger rna
|
CA2928186A1
(en)
|
2013-10-22 |
2015-04-30 |
Shire Human Genetic Therapies, Inc. |
Mrna therapy for phenylketonuria
|
ES2954366T3
(es)
|
2013-10-22 |
2023-11-21 |
Translate Bio Inc |
Terapia de ácido ribonucleico mensajero para la deficiencia de argininosuccinato sintetasa
|
WO2015065505A1
(en)
*
|
2013-10-29 |
2015-05-07 |
Duke University |
Use of cyp27a1 inhibitors, statin, or lxr antagonists alone or in combination with conventional therapy for the treatment of breast cancer
|
CA2925021A1
(en)
|
2013-11-01 |
2015-05-07 |
Curevac Ag |
Modified rna with decreased immunostimulatory properties
|
EP3542802A1
(en)
|
2013-11-01 |
2019-09-25 |
CureVac AG |
Modified rna with decreased immunostimulatory properties
|
US10801070B2
(en)
|
2013-11-25 |
2020-10-13 |
The Broad Institute, Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer
|
US11725237B2
(en)
|
2013-12-05 |
2023-08-15 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
EP3082760A1
(en)
|
2013-12-19 |
2016-10-26 |
Novartis AG |
LEPTIN mRNA COMPOSITIONS AND FORMULATIONS
|
KR20160101073A
(ko)
|
2013-12-20 |
2016-08-24 |
더 브로드 인스티튜트, 인코퍼레이티드 |
신생항원 백신과의 병용 요법
|
JP6584414B2
(ja)
|
2013-12-30 |
2019-10-02 |
キュアバック アーゲー |
人工核酸分子
|
KR102399799B1
(ko)
|
2013-12-30 |
2022-05-18 |
큐어백 아게 |
인공 핵산 분자
|
US11254951B2
(en)
|
2014-12-30 |
2022-02-22 |
Curevac Ag |
Artificial nucleic acid molecules
|
EP4249036A3
(en)
|
2014-01-31 |
2023-10-25 |
Factor Bioscience Inc. |
Methods and products for nucleic acid production and delivery
|
US10370680B2
(en)
|
2014-02-24 |
2019-08-06 |
Sangamo Therapeutics, Inc. |
Method of treating factor IX deficiency using nuclease-mediated targeted integration
|
JP2017507946A
(ja)
|
2014-02-26 |
2017-03-23 |
エスリス ゲーエムベーハーethris GmbH |
Rnaを胃腸内投与するための組成物
|
CA2942407C
(en)
|
2014-03-14 |
2023-09-26 |
Cibus Us Llc |
Methods and compositions for increasing efficiency of targeted gene modification using oligonucleotide-mediated gene repair
|
CA2944128C
(en)
*
|
2014-04-01 |
2022-08-30 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Capped and uncapped rna molecules and block copolymers for intracellular delivery of rna
|
PT3134131T
(pt)
|
2014-04-23 |
2022-03-24 |
Modernatx Inc |
Vacinas de ácidos nucleicos
|
ES2750661T3
(es)
|
2014-04-25 |
2020-03-26 |
Translate Bio Inc |
Métodos para la purificación de ARN mensajero
|
JP6557722B2
(ja)
|
2014-05-30 |
2019-08-07 |
シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド |
核酸の送達のための生分解性脂質
|
BR112016026980B1
(pt)
|
2014-06-10 |
2022-05-03 |
Curevac Real Estate Gmbh |
Método para sintetizar uma molécula de rna de uma dada sequência
|
GB201410693D0
(en)
|
2014-06-16 |
2014-07-30 |
Univ Southampton |
Splicing modulation
|
WO2015196128A2
(en)
|
2014-06-19 |
2015-12-23 |
Moderna Therapeutics, Inc. |
Alternative nucleic acid molecules and uses thereof
|
ES2964588T3
(es)
|
2014-06-24 |
2024-04-08 |
Translate Bio Inc |
Composiciones enriquecidas estereoquímicamente para la administración de ácidos nucleicos
|
CA2953341C
(en)
|
2014-06-25 |
2023-01-24 |
Acuitas Therapeutics Inc. |
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
WO2016011226A1
(en)
|
2014-07-16 |
2016-01-21 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
JP2017522028A
(ja)
|
2014-07-16 |
2017-08-10 |
モデルナティエックス インコーポレイテッドModernaTX,Inc. |
環状ポリヌクレオチド
|
US20170210788A1
(en)
*
|
2014-07-23 |
2017-07-27 |
Modernatx, Inc. |
Modified polynucleotides for the production of intrabodies
|
KR102617137B1
(ko)
|
2014-09-15 |
2023-12-27 |
칠드런'즈 메디컬 센터 코포레이션 |
히스톤 h3-리신 트리메틸화를 제거함으로써 체세포 핵 이식(scnt) 효율을 증가시키는 방법 및 조성물
|
BR112017005245A2
(pt)
|
2014-09-19 |
2017-12-12 |
Regeneron Pharma |
animal não humano geneticamente modificado, métodos para produzir célula t, hibridoma de célula t, um ácido nucleico, um anticorpo específico, uma célula humana, um animal não humano geneticamente modificado e para induzir uma resposta imunológica, célula, hibridoma de célula t, ácido nucleico, anticorpo específico, receptor de antígeno quimérico, embrião não humano, locus de um receptor de antígeno quimérico, e, composição de ácidos nucleicos.
|
WO2016045732A1
(en)
|
2014-09-25 |
2016-03-31 |
Biontech Rna Pharmaceuticals Gmbh |
Stable formulations of lipids and liposomes
|
AU2015327836B2
(en)
|
2014-10-03 |
2021-07-01 |
Cold Spring Harbor Laboratory |
Targeted augmentation of nuclear gene output
|
JP6728156B2
(ja)
|
2014-11-02 |
2020-07-22 |
アークトゥラス・セラピューティクス・インコーポレイテッドArcturus Therapeutics,Inc. |
メッセンジャーuna分子およびその使用
|
BR112017009497A2
(pt)
|
2014-11-05 |
2018-02-06 |
Voyager Therapeutics, Inc. |
polinucleotídeos de aadc para o tratamento da doença de parkinson
|
WO2016077125A1
(en)
|
2014-11-10 |
2016-05-19 |
Moderna Therapeutics, Inc. |
Alternative nucleic acid molecules containing reduced uracil content and uses thereof
|
EP3218508A4
(en)
*
|
2014-11-10 |
2018-04-18 |
Modernatx, Inc. |
Multiparametric nucleic acid optimization
|
ES2791152T3
(es)
|
2014-12-12 |
2020-11-03 |
Curevac Ag |
Moléculas de ácido nucleico artificiales para una expresión proteica mejorada
|
WO2016100975A1
(en)
|
2014-12-19 |
2016-06-23 |
Massachsetts Institute Ot Technology |
Molecular biomarkers for cancer immunotherapy
|
EP3034539A1
(en)
|
2014-12-19 |
2016-06-22 |
Ethris GmbH |
Compositions for introducing nucleic acid into cells
|
WO2016100977A1
(en)
|
2014-12-19 |
2016-06-23 |
The Broad Institute Inc. |
Methods for profiling the t-cel- receptor repertoire
|
WO2016128060A1
(en)
|
2015-02-12 |
2016-08-18 |
Biontech Ag |
Predicting t cell epitopes useful for vaccination
|
CA2976376A1
(en)
|
2015-02-13 |
2016-08-18 |
Factor Bioscience Inc. |
Nucleic acid products and methods of administration thereof
|
US20180303925A1
(en)
*
|
2015-04-27 |
2018-10-25 |
The Trustees Of The University Of Pennsylvania |
Nucleoside-Modified RNA For Inducing an Adaptive Immune Response
|
CN116196401A
(zh)
|
2015-05-20 |
2023-06-02 |
博德研究所 |
共有的新抗原
|
TWI750122B
(zh)
|
2015-06-09 |
2021-12-21 |
美商博德研究所有限公司 |
用於贅瘤疫苗之調配物及其製備方法
|
WO2017004143A1
(en)
|
2015-06-29 |
2017-01-05 |
Acuitas Therapeutics Inc. |
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
AU2016287436B2
(en)
|
2015-06-30 |
2022-02-17 |
Ethris Gmbh |
UTRs increasing the translation efficiency of RNA molecules
|
US10584343B2
(en)
|
2015-07-16 |
2020-03-10 |
Cornell University |
Methods of enhancing translation ability of RNA molecules, treatments, and kits
|
US11364292B2
(en)
|
2015-07-21 |
2022-06-21 |
Modernatx, Inc. |
CHIKV RNA vaccines
|
US11564893B2
(en)
|
2015-08-17 |
2023-01-31 |
Modernatx, Inc. |
Methods for preparing particles and related compositions
|
WO2017049286A1
(en)
|
2015-09-17 |
2017-03-23 |
Moderna Therapeutics, Inc. |
Polynucleotides containing a morpholino linker
|
EP3359670B2
(en)
|
2015-10-05 |
2024-02-14 |
ModernaTX, Inc. |
Methods for therapeutic administration of messenger ribonucleic acid drugs
|
WO2017059902A1
(en)
|
2015-10-07 |
2017-04-13 |
Biontech Rna Pharmaceuticals Gmbh |
3' utr sequences for stabilization of rna
|
KR20220105174A
(ko)
|
2015-10-09 |
2022-07-26 |
유니버시티 오브 사우스앰톤 |
유전자 발현의 조절 및 탈조절된 단백질 발현의 스크리닝
|
EP4089175A1
(en)
|
2015-10-13 |
2022-11-16 |
Duke University |
Genome engineering with type i crispr systems in eukaryotic cells
|
EP3362460A1
(en)
*
|
2015-10-16 |
2018-08-22 |
Modernatx, Inc. |
Mrna cap analogs and methods of mrna capping
|
US20190218546A1
(en)
|
2015-10-16 |
2019-07-18 |
Modernatx, Inc. |
Mrna cap analogs with modified phosphate linkage
|
US11866754B2
(en)
|
2015-10-16 |
2024-01-09 |
Modernatx, Inc. |
Trinucleotide mRNA cap analogs
|
MD3718565T2
(ro)
|
2015-10-22 |
2022-09-30 |
Modernatx Inc |
Vaccinuri împotriva virusului respirator
|
KR20180094859A
(ko)
|
2015-10-22 |
2018-08-24 |
모더나티엑스, 인크. |
수두 대상포진 바이러스 (vzv)를 위한 핵산 백신
|
EP3364950A4
(en)
|
2015-10-22 |
2019-10-23 |
ModernaTX, Inc. |
VACCINES AGAINST TROPICAL DISEASES
|
CA3002922A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
AU2016343803B2
(en)
|
2015-10-28 |
2021-04-29 |
Acuitas Therapeutics, Inc. |
Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
MA43415A
(fr)
*
|
2015-12-09 |
2018-10-17 |
Modernatx Inc |
Arnm modifié codant pour une uridine diphosphate glucuronosyltransférase et utilisations associées
|
WO2017100551A1
(en)
|
2015-12-09 |
2017-06-15 |
Alexion Pharmaceuticals, Inc. |
HETEROLOGOUS UTR SEQUENCES FOR ENHANCED mRNA EXPRESSION
|
US20210108252A1
(en)
|
2015-12-09 |
2021-04-15 |
Novartis Ag |
Label-free analysis of rna capping efficiency using rnase h, probes and liquid chromatography/mass spectrometry
|
EP3964200A1
(en)
|
2015-12-10 |
2022-03-09 |
ModernaTX, Inc. |
Compositions and methods for delivery of therapeutic agents
|
US11096956B2
(en)
|
2015-12-14 |
2021-08-24 |
Stoke Therapeutics, Inc. |
Antisense oligomers and uses thereof
|
CN109312343B
(zh)
|
2015-12-14 |
2022-09-27 |
冷泉港实验室 |
用于治疗常染色体显性精神发育迟滞5型和Dravet综合征的反义寡聚体
|
WO2017106799A1
(en)
|
2015-12-17 |
2017-06-22 |
Modernatx, Inc. |
POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASE
|
EP3405579A1
(en)
*
|
2016-01-22 |
2018-11-28 |
Modernatx, Inc. |
Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
|
WO2017138986A1
(en)
|
2016-02-09 |
2017-08-17 |
Cibus Us Llc |
Methods and compositions for increasing efficiency of targeted gene modification using oligonucleotide-mediated gene repair
|
EP3423106B1
(en)
|
2016-03-01 |
2022-07-27 |
Alexion Pharmaceuticals, Inc. |
Biodegradable activated polymers for therapeutic delivery
|
US11318197B2
(en)
|
2016-03-03 |
2022-05-03 |
Duke University |
Compositions and methods for inducing HIV-1 antibodies
|
CA3016352A1
(en)
|
2016-03-03 |
2017-09-08 |
Duke University |
Compositions and methods for inducing hiv-1 antibodies
|
WO2017153936A1
(en)
*
|
2016-03-10 |
2017-09-14 |
Novartis Ag |
Chemically modified messenger rna's
|
RU2759737C2
(ru)
|
2016-03-31 |
2021-11-17 |
Этрис Гмбх |
Новые минимальные utr-последовательности
|
WO2017173354A2
(en)
*
|
2016-04-01 |
2017-10-05 |
University Of Iowa Research Foundation |
METABOLICALLY STABILIZED DOUBLE STRANDED mRNA
|
EP3443001A4
(en)
|
2016-04-11 |
2020-04-29 |
Obsidian Therapeutics, Inc. |
REGULATED BIOCIRCUIT SYSTEMS
|
EP3442590A2
(en)
|
2016-04-13 |
2019-02-20 |
Modernatx, Inc. |
Lipid compositions and their uses for intratumoral polynucleotide delivery
|
AU2017254477A1
(en)
|
2016-04-18 |
2018-11-01 |
Jennifer G. ABELIN |
Improved HLA epitope prediction
|
MX2018013509A
(es)
|
2016-05-18 |
2019-03-28 |
Modernatx Inc |
Polinucleotidos que codifican interleucina-12 (il12) y sus usos de los mismos.
|
EP3458107B1
(en)
|
2016-05-18 |
2024-03-13 |
ModernaTX, Inc. |
Polynucleotides encoding jagged1 for the treatment of alagille syndrome
|
SG11201810256XA
(en)
|
2016-05-18 |
2018-12-28 |
Modernatx Inc |
Polynucleotides encoding relaxin
|
MA45053A
(fr)
*
|
2016-05-18 |
2019-03-27 |
Modernatx Inc |
Polynucléotides codant pour un régulateur de conductance transmembranaire de fibrose kystique pour le traitement de la fibrose kystique
|
CN116458475A
(zh)
|
2016-06-03 |
2023-07-21 |
瑞泽恩制药公司 |
表达外源末端脱氧核苷酸转移酶的非人动物
|
KR101916652B1
(ko)
|
2016-06-29 |
2018-11-08 |
올릭스 주식회사 |
작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도
|
US10927383B2
(en)
|
2016-06-30 |
2021-02-23 |
Ethris Gmbh |
Cas9 mRNAs
|
MX2019000205A
(es)
|
2016-07-07 |
2019-09-23 |
Rubius Therapeutics Inc |
Composiciones y metodos relacionados con sistemas celulares terapeuticos que expresan arn exogeno.
|
US10576167B2
(en)
|
2016-08-17 |
2020-03-03 |
Factor Bioscience Inc. |
Nucleic acid products and methods of administration thereof
|
ES2928475T3
(es)
|
2016-09-14 |
2022-11-18 |
Modernatx Inc |
Composiciones de ARN de alta pureza y métodos para su preparación
|
CA3039089A1
(en)
|
2016-10-03 |
2018-04-12 |
Duke University |
Methods to identify immunogens by targeting improbable mutations
|
KR102305215B1
(ko)
|
2016-10-14 |
2021-09-28 |
프리시젼 바이오사이언시스 인코포레이티드 |
B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제
|
MA46584A
(fr)
|
2016-10-21 |
2019-08-28 |
Modernatx Inc |
Vaccin contre le cytomégalovirus humain
|
US11084859B2
(en)
|
2016-10-24 |
2021-08-10 |
Orionis Biosciences BV |
Targeted mutant interferon-gamma and uses thereof
|
US20190274968A1
(en)
*
|
2016-10-27 |
2019-09-12 |
The Trustees Of The University Of Pennsylvania |
Nucleoside-modified rna for inducing an adaptive immune response
|
US10907165B2
(en)
|
2016-10-31 |
2021-02-02 |
Cornell University |
Methods of enhancing translation ability and stability of RNA molecules, treatments, and kits
|
CN110114058B
(zh)
|
2016-11-10 |
2023-05-26 |
川斯勒佰尔公司 |
用于递送mrna的改进的基于ice的脂质纳米颗粒制剂
|
WO2018089851A2
(en)
|
2016-11-11 |
2018-05-17 |
Modernatx, Inc. |
Influenza vaccine
|
WO2018111967A1
(en)
|
2016-12-13 |
2018-06-21 |
Modernatx, Inc. |
Rna affinity purification
|
WO2018132572A1
(en)
|
2017-01-11 |
2018-07-19 |
The Board Of Trustees Of The Leland Stanford Junior University |
R-spondin (rspo) surrogate molecules
|
JP7317715B2
(ja)
|
2017-01-11 |
2023-07-31 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
ジカウイルスに対する免疫応答を誘導するためのヌクレオシド改変rna
|
US11549149B2
(en)
|
2017-01-24 |
2023-01-10 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
WO2018140821A1
(en)
|
2017-01-26 |
2018-08-02 |
Surrozen, Inc. |
Tissue-specific wnt signal enhancing molecules and uses thereof
|
CA3051252A1
(en)
|
2017-02-01 |
2018-08-09 |
Modernatx, Inc. |
Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
|
WO2018144999A1
(en)
|
2017-02-06 |
2018-08-09 |
Orionis Biosciences, Inc. |
Targeted engineered interferon and uses thereof
|
CA3052523A1
(en)
|
2017-02-06 |
2018-08-09 |
Orionis Biosciences Nv |
Targeted chimeric proteins and uses thereof
|
WO2018146557A2
(en)
*
|
2017-02-10 |
2018-08-16 |
Dong Ki Lee |
Long double-stranded rna for rna interference
|
MA47607A
(fr)
|
2017-02-27 |
2020-01-01 |
Translate Bio Inc |
Synthèse à grande échelle d'arn messager
|
MX2019010155A
(es)
|
2017-02-27 |
2020-12-10 |
Translate Bio Inc |
Arnm de cftr optimizado por codón novedoso.
|
KR20190124750A
(ko)
|
2017-02-28 |
2019-11-05 |
사노피 |
치료적 rna
|
US11407800B2
(en)
|
2017-02-28 |
2022-08-09 |
Arcturus Therapeutics, Inc. |
Translatable molecules and synthesis thereof
|
US11752206B2
(en)
|
2017-03-15 |
2023-09-12 |
Modernatx, Inc. |
Herpes simplex virus vaccine
|
MA52262A
(fr)
|
2017-03-15 |
2020-02-19 |
Modernatx Inc |
Vaccin à large spectre contre le virus de la grippe
|
MA47787A
(fr)
|
2017-03-15 |
2020-01-22 |
Modernatx Inc |
Vaccin contre le virus respiratoire syncytial
|
WO2018170270A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Varicella zoster virus (vzv) vaccine
|
US20200030432A1
(en)
|
2017-03-17 |
2020-01-30 |
Modernatx, Inc. |
Zoonotic disease rna vaccines
|
MA48047A
(fr)
|
2017-04-05 |
2020-02-12 |
Modernatx Inc |
Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée
|
WO2018188730A1
(en)
|
2017-04-11 |
2018-10-18 |
Biontech Rna Pharmaceuticals Gmbh |
Rna for treatment of autoimmune diseases
|
US11357856B2
(en)
|
2017-04-13 |
2022-06-14 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
AU2018258575A1
(en)
|
2017-04-27 |
2019-11-07 |
The Johns Hopkins University |
Hepatitis C virus gene sequences and methods of use therefor
|
US11820728B2
(en)
|
2017-04-28 |
2023-11-21 |
Acuitas Therapeutics, Inc. |
Carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
JP2020518648A
(ja)
|
2017-05-08 |
2020-06-25 |
グリットストーン オンコロジー インコーポレイテッド |
アルファウイルス新生抗原ベクター
|
IL270631B2
(en)
|
2017-05-16 |
2024-03-01 |
Translate Bio Inc |
Treatment of cystic fibrosis through the administration of mRNA with an optimal codon encoding ctfr
|
EP3630964A4
(en)
|
2017-05-31 |
2021-03-03 |
Ultragenyx Pharmaceutical Inc. |
THERAPEUTIC AGENTS FOR GLYCOGEN STORAGE DISEASE TYPE III
|
BR112019025888A2
(pt)
|
2017-06-07 |
2020-06-30 |
Regeneron Pharmaceuticals, Inc. |
polinucleotídeo que codifica uma proteína terapêutica multidomínio, vetor de terapia gênica, proteína terapêutica multidomínio recombinante, método de expressão, métodos para reduzir o acúmulo de glicogênio em um tecido em um paciente em necessidade, para reduzir o acúmulo de glicogênio em um tecido em um paciente em necessidade epara tratar a deficiência enzimática em um paciente em necessidade e/ou tolerar o paciente à enzima para a qual é deficiente, anticorpo anti-cd63 ou fragmento de ligação a antígeno, e, composição farmacêutica
|
US20200131498A1
(en)
|
2017-06-14 |
2020-04-30 |
Modernatx, Inc. |
Polynucleotides encoding methylmalonyl-coa mutase
|
EP3638292A1
(en)
*
|
2017-06-14 |
2020-04-22 |
ModernaTX, Inc. |
Polynucleotides encoding coagulation factor viii
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
US11786607B2
(en)
|
2017-06-15 |
2023-10-17 |
Modernatx, Inc. |
RNA formulations
|
US10034951B1
(en)
|
2017-06-21 |
2018-07-31 |
New England Biolabs, Inc. |
Use of thermostable RNA polymerases to produce RNAs having reduced immunogenicity
|
KR20200024905A
(ko)
*
|
2017-07-04 |
2020-03-09 |
큐어백 아게 |
신규 핵산 분자
|
US11628227B2
(en)
*
|
2017-07-05 |
2023-04-18 |
Wisconsin Alumni Research Foundation |
Mineral coated microparticles for gene delivery in chronic wound therapy
|
MA49634A
(fr)
|
2017-07-21 |
2020-05-27 |
Modernatx Inc |
Arnm modifié codant pour une propionyl-coa-carboxylase et utilisations associées
|
US20200179494A1
(en)
|
2017-07-24 |
2020-06-11 |
Modernatx, Inc. |
Modified mRNA Encoding a Glucose 6 Phosphatase and Uses Thereof
|
US11639329B2
(en)
|
2017-08-16 |
2023-05-02 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
WO2019036028A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
|
CN111246854A
(zh)
|
2017-08-17 |
2020-06-05 |
宾夕法尼亚大学理事会 |
编码单纯疱疹病毒糖蛋白的修饰mrna疫苗及其用途
|
WO2019036030A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
|
WO2019036683A1
(en)
|
2017-08-18 |
2019-02-21 |
Modernatx, Inc. |
ANALYTICAL METHODS BY HPLC
|
MA49922A
(fr)
|
2017-08-18 |
2021-06-02 |
Modernatx Inc |
Procédés pour analyse par clhp
|
EP3668971B8
(en)
|
2017-08-18 |
2024-05-29 |
ModernaTX, Inc. |
Rna polymerase variants
|
RS65031B1
(sr)
|
2017-08-25 |
2024-02-29 |
Stoke Therapeutics Inc |
Antisens oligomeri za lečenje stanja i bolesti
|
US11744801B2
(en)
|
2017-08-31 |
2023-09-05 |
Modernatx, Inc. |
Methods of making lipid nanoparticles
|
US10653767B2
(en)
|
2017-09-14 |
2020-05-19 |
Modernatx, Inc. |
Zika virus MRNA vaccines
|
WO2019070730A1
(en)
|
2017-10-02 |
2019-04-11 |
Duke University |
MOSAIC ENVELOPES OF HIV-1 TO INDUCE ADCC RESPONSES
|
US20210180053A1
(en)
|
2017-11-01 |
2021-06-17 |
Novartis Ag |
Synthetic rnas and methods of use
|
EP3714047A2
(en)
|
2017-11-22 |
2020-09-30 |
ModernaTX, Inc. |
Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria
|
EP3714048A1
(en)
|
2017-11-22 |
2020-09-30 |
Modernatx, Inc. |
Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders
|
EP3724355A1
(en)
|
2017-12-15 |
2020-10-21 |
Novartis AG |
Polya tail length analysis of rna by mass spectrometry
|
CN111818943A
(zh)
|
2018-01-04 |
2020-10-23 |
伊科尼克治疗公司 |
抗组织因子抗体、抗体-药物缀合物及相关方法
|
CA3087266A1
(en)
|
2018-01-09 |
2019-07-18 |
Cibus Us Llc |
Shatterproof genes and mutations
|
MA54676A
(fr)
|
2018-01-29 |
2021-11-17 |
Modernatx Inc |
Vaccins à base d'arn contre le vrs
|
US11896643B2
(en)
|
2018-02-05 |
2024-02-13 |
Orionis Biosciences, Inc. |
Fibroblast binding agents and use thereof
|
CN112040985A
(zh)
|
2018-02-07 |
2020-12-04 |
瑞泽恩制药公司 |
用于递送治疗性蛋白质的方法和组合物
|
WO2019158583A1
(en)
|
2018-02-13 |
2019-08-22 |
Ethris Gmbh |
Polyribonucleotide containing deuterated nucleotides
|
JP2021518331A
(ja)
*
|
2018-03-13 |
2021-08-02 |
ザ・ボード・オブ・トラステイーズ・オブ・ザ・リーランド・スタンフオード・ジユニア・ユニバーシテイ |
細胞加齢の反転のための一過性細胞リプログラミング
|
AU2019252527B2
(en)
|
2018-04-12 |
2024-02-22 |
Precision Biosciences, Inc. |
Optimized engineered nucleases having specificity for the human T cell receptor alpha constant region gene
|
US11142750B2
(en)
|
2018-04-12 |
2021-10-12 |
Precision Biosciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
|
AU2019258679A1
(en)
|
2018-04-25 |
2020-10-15 |
Ethris Gmbh |
Cryoprotective agents for particulate formulations
|
EP3806888B1
(en)
|
2018-06-12 |
2024-01-31 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
CN108956566B
(zh)
*
|
2018-07-06 |
2020-10-02 |
军事科学院军事医学研究院环境医学与作业医学研究所 |
基于切刻内切酶和杂交链式反应双重放大的上转换荧光检测多氯联苯试剂盒及检测方法
|
CN112930396B
(zh)
|
2018-08-24 |
2024-05-24 |
川斯勒佰尔公司 |
用于纯化信使rna的方法
|
US20230009009A1
(en)
*
|
2018-09-13 |
2023-01-12 |
Modernatx, Inc. |
Polynucleotides encoding glucose-6-phosphatase for the treatment of glycogen storage disease
|
EP3863645A4
(en)
*
|
2018-09-13 |
2022-11-16 |
ModernaTX, Inc. |
MODIFIED mRNA FOR THE TREATMENT OF FAMILY PROGRESSIVE INTRAHEPATIC CHOLESTASIS DISORDERS
|
WO2020069169A1
(en)
*
|
2018-09-27 |
2020-04-02 |
Modernatx, Inc. |
Polynucleotides encoding arginase 1 for the treatment of arginase deficiency
|
US20210382068A1
(en)
|
2018-10-02 |
2021-12-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
EP3870600A1
(en)
|
2018-10-24 |
2021-09-01 |
Obsidian Therapeutics, Inc. |
Er tunable protein regulation
|
ES2960692T3
(es)
|
2018-12-06 |
2024-03-06 |
Arcturus Therapeutics Inc |
Composiciones y métodos para el tratamiento de la deficiencia de ornitina transcarbamilasa
|
CN111303283A
(zh)
|
2018-12-12 |
2020-06-19 |
上海君实生物医药科技股份有限公司 |
抗il-17a抗体及其应用
|
WO2020131586A2
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
EP3898661A1
(en)
|
2018-12-21 |
2021-10-27 |
Precision BioSciences, Inc. |
Genetic modification of the hydroxyacid oxidase 1 gene for treatment of primary hyperoxaluria
|
AU2020205717A1
(en)
|
2019-01-11 |
2021-08-12 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
US20220098621A1
(en)
|
2019-02-05 |
2022-03-31 |
Emendobio Inc. |
Crispr compositions and methods for promoting gene editing of ribosomal protein s19 (rps19) gene
|
WO2020168466A1
(en)
|
2019-02-19 |
2020-08-27 |
Stemirna Therapeutics Co., Ltd. |
Modified nucleoside and synthetic methods thereof
|
US11851694B1
(en)
|
2019-02-20 |
2023-12-26 |
Modernatx, Inc. |
High fidelity in vitro transcription
|
AU2020224103A1
(en)
|
2019-02-20 |
2021-09-16 |
Modernatx, Inc. |
Rna polymerase variants for co-transcriptional capping
|
CN113661242A
(zh)
*
|
2019-03-25 |
2021-11-16 |
旗舰创业创新第六有限责任公司 |
包含经修饰的环状多核糖核苷酸的组合物及其用途
|
CA3135799A1
(en)
|
2019-04-03 |
2020-10-08 |
Precision Biosciences, Inc. |
Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir)
|
CA3136265A1
(en)
|
2019-04-05 |
2020-10-08 |
Precision Biosciences, Inc. |
Methods of preparing populations of genetically-modified immune cells
|
WO2020231702A1
(en)
*
|
2019-05-11 |
2020-11-19 |
Youngsuk Yi |
Compositions and methods containing exosomes
|
CA3140019A1
(en)
|
2019-05-30 |
2020-12-03 |
Gritstone Bio, Inc. |
Modified adenoviruses
|
EP4001308A4
(en)
|
2019-07-15 |
2023-08-23 |
Shanghai Junshi Biosciences Co., Ltd. |
ANTI-TIGIT ANTIBODIES AND THEIR APPLICATION
|
US20220273715A1
(en)
|
2019-07-25 |
2022-09-01 |
Precision Biosciences, Inc. |
Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus
|
US10501404B1
(en)
|
2019-07-30 |
2019-12-10 |
Factor Bioscience Inc. |
Cationic lipids and transfection methods
|
WO2021030271A2
(en)
|
2019-08-09 |
2021-02-18 |
Nutcracker Therapeutics, Inc. |
Methods and apparatuses for manufacturing for removing material from a therapeutic composition
|
CN112390838A
(zh)
*
|
2019-08-14 |
2021-02-23 |
斯微(上海)生物科技有限公司 |
一种改性核苷及其合成方法
|
DE102019122014A1
(de)
|
2019-08-15 |
2021-02-18 |
Technische Universität Darmstadt |
Reduktion der Knochenresorption, insbesondere bei chronischen Gelenkerkrankungen
|
AU2020333851A1
(en)
|
2019-08-20 |
2022-03-31 |
Precision Biosciences, Inc. |
Lymphodepletion dosing regimens for cellular immunotherapies
|
CA3155003A1
(en)
|
2019-09-20 |
2021-03-25 |
Translate Bio, Inc. |
Mrna encoding engineered cftr
|
EP4041400A1
(en)
|
2019-10-09 |
2022-08-17 |
Translate Bio, Inc. |
Compositions, methods and uses of messenger rna
|
JP2022553042A
(ja)
|
2019-10-21 |
2022-12-21 |
トランスレイト バイオ, インコーポレイテッド |
メッセンジャーrnaの組成物、方法および使用
|
CA3158491A1
(en)
|
2019-10-24 |
2021-04-29 |
Novago Therapeutics Ag |
Novel anti-nogo-a antibodies
|
WO2021087305A1
(en)
|
2019-10-30 |
2021-05-06 |
Precision Biosciences, Inc. |
Cd20 chimeric antigen receptors and methods of use for immunotherapy
|
WO2021113543A1
(en)
|
2019-12-06 |
2021-06-10 |
Precision Biosciences, Inc. |
Methods for cancer immunotherapy, using lymphodepletion regimens and cd19, cd20 or bcma allogeneic car t cells
|
WO2021113765A1
(en)
|
2019-12-06 |
2021-06-10 |
Precision Biosciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
|
CN115515559A
(zh)
|
2019-12-20 |
2022-12-23 |
翻译生物公司 |
信使rna的直肠递送
|
WO2021127641A1
(en)
|
2019-12-20 |
2021-06-24 |
Translate Bio, Inc. |
Improved process of preparing mrna-loaded lipid nanoparticles
|
KR20220129567A
(ko)
|
2019-12-31 |
2022-09-23 |
엘릭서젠 쎄라퓨틱스, 인크. |
핵산 및 단백질의 세포 및 조직으로의 온도-기반 일시적 전달
|
WO2021142245A1
(en)
|
2020-01-10 |
2021-07-15 |
Translate Bio, Inc. |
Compounds, pharmaceutical compositions and methods for modulating expression of muc5b in lung cells and tissues
|
US11576966B2
(en)
|
2020-02-04 |
2023-02-14 |
CureVac SE |
Coronavirus vaccine
|
WO2021163134A1
(en)
|
2020-02-10 |
2021-08-19 |
Translate Bio, Inc. |
Methods and compositions for messenger rna purification
|
CN115398546A
(zh)
|
2020-02-18 |
2022-11-25 |
翻译生物公司 |
用于信使rna体外转录的改进方法
|
WO2021169932A1
(zh)
|
2020-02-24 |
2021-09-02 |
中国科学院微生物研究所 |
新型冠状病毒的人源单克隆抗体及其应用
|
WO2021173840A1
(en)
|
2020-02-25 |
2021-09-02 |
Translate Bio, Inc. |
Improved processes of preparing mrna-loaded lipid nanoparticles
|
EP4132478A1
(en)
|
2020-04-09 |
2023-02-15 |
Finncure Oy |
Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
|
GB202307565D0
(en)
|
2020-04-22 |
2023-07-05 |
BioNTech SE |
Coronavirus vaccine
|
CA3177940A1
(en)
|
2020-05-07 |
2021-11-11 |
Anusha DIAS |
Optimized nucleotide sequences encoding sars-cov-2 antigens
|
KR20230020991A
(ko)
|
2020-05-07 |
2023-02-13 |
트랜슬레이트 바이오 인코포레이티드 |
최적화된 뉴클레오티드 서열의 생성
|
US20230181619A1
(en)
|
2020-05-07 |
2023-06-15 |
Translate Bio, Inc. |
Improved compositions for cftr mrna therapy
|
US20230190954A1
(en)
|
2020-05-07 |
2023-06-22 |
Translate Bio, Inc. |
Composition and methods for treatment of primary ciliary dyskinesia
|
WO2021231107A1
(en)
|
2020-05-11 |
2021-11-18 |
Stoke Therapeutics, Inc. |
Opa1 antisense oligomers for treatment of conditions and diseases
|
WO2021231259A1
(en)
|
2020-05-11 |
2021-11-18 |
Precision Biosciences, Inc. |
Self-limiting viral vectors encoding nucleases
|
EP4150068A1
(en)
|
2020-05-12 |
2023-03-22 |
Precision BioSciences, Inc. |
Treatment of retinitis pigmentosa using improved engineered meganucleases
|
JP2023526284A
(ja)
|
2020-05-15 |
2023-06-21 |
トランスレイト バイオ, インコーポレイテッド |
mRNA送達のための脂質ナノ粒子製剤
|
WO2021245184A1
(en)
|
2020-06-02 |
2021-12-09 |
Neurimmune Ag |
HUMAN ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2)
|
EP4179112A2
(en)
|
2020-07-13 |
2023-05-17 |
The Board of Trustees of the Leland Stanford Junior University |
Systems and methods to assess rna stability
|
AU2021307516A1
(en)
|
2020-07-13 |
2023-03-02 |
Shanghai Junshi Biosciences Co., Ltd. |
Anti-CLDN-18.2 antibody and use thereof
|
CN116096702A
(zh)
|
2020-07-16 |
2023-05-09 |
爱康泰生治疗公司 |
用于脂质纳米颗粒的阳离子脂质
|
EP4201958A1
(en)
|
2020-07-21 |
2023-06-28 |
Shanghai Junshi Biosciences Co., Ltd. |
Anti-ctla-4 antibody and use thereof
|
WO2022031935A1
(en)
|
2020-08-05 |
2022-02-10 |
Dragonfly Therapeutics, Inc. |
Antibodies targeting egfr and use thereof
|
WO2022032196A2
(en)
|
2020-08-06 |
2022-02-10 |
Gritstone Bio, Inc. |
Multiepitope vaccine cassettes
|
EP4192875A1
(en)
|
2020-08-10 |
2023-06-14 |
Precision BioSciences, Inc. |
Antibodies and fragments specific for b-cell maturation antigen and uses thereof
|
AU2021329403A1
(en)
|
2020-08-21 |
2023-05-04 |
Precision Biosciences, Inc. |
Engineered meganucleases having specificity for a recognition sequence in the transthyretin gene
|
US11406703B2
(en)
|
2020-08-25 |
2022-08-09 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
WO2022047427A2
(en)
|
2020-08-31 |
2022-03-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Systems and methods for producing rna constructs with increased translation and stability
|
CA3194863A1
(en)
|
2020-10-06 |
2022-04-14 |
Shrirang KARVE |
Improved process and formulation of lipid nanoparticles
|
US20230365995A1
(en)
|
2020-10-07 |
2023-11-16 |
Precision Biosciences, Inc. |
Lipid nanoparticle compositions
|
KR20230087536A
(ko)
|
2020-10-12 |
2023-06-16 |
트랜슬레이트 바이오 인코포레이티드 |
Mrna-로딩된 지질 나노입자를 제조하는 개선된 프로세스
|
US20220133631A1
(en)
|
2020-10-12 |
2022-05-05 |
Translate Bio, Inc. |
Process of preparing ice-based lipid nanoparticles
|
CA3195281A1
(en)
*
|
2020-10-13 |
2022-04-21 |
Hamideh Parhiz |
In vivo targeting of cd4+-t cells for mrna therapeutics
|
JP2023545503A
(ja)
|
2020-10-15 |
2023-10-30 |
トランスレイト バイオ, インコーポレイテッド |
メッセンジャーrnaの大規模合成
|
EP4203997A1
(en)
|
2020-10-26 |
2023-07-05 |
Pécsi Tudományegyetem |
Vaccine platform
|
GB202017649D0
(en)
|
2020-11-09 |
2020-12-23 |
Autolus Ltd |
Polypeptide
|
EP4240326A1
(en)
|
2020-11-09 |
2023-09-13 |
Translate Bio, Inc. |
Improved compositions for delivery of codon-optimized mrna
|
KR20230118841A
(ko)
|
2020-11-12 |
2023-08-14 |
프리시젼 바이오사이언시스 인코포레이티드 |
디스트로핀 유전자 내의 인식 서열에 대해 특이성을 갖는 조작된 메가뉴클레아제
|
WO2022106860A1
(en)
|
2020-11-20 |
2022-05-27 |
Pécsi Tudományegyetem |
Recombinant peptides for use in therapy
|
CN117098541A
(zh)
|
2020-11-25 |
2023-11-21 |
阿卡格拉医药公司 |
用于递送核酸的脂质纳米粒及相关使用方法
|
MX2023006133A
(es)
|
2020-11-25 |
2023-07-18 |
Translate Bio Inc |
Formulaciones estables de nanopartículas de lipídos líquidos.
|
MX2023007574A
(es)
|
2020-12-22 |
2023-09-29 |
CureVac SE |
"vacuna de arn contra variantes de sars-cov-2.
|
WO2022150616A1
(en)
|
2021-01-08 |
2022-07-14 |
Precision Biosciences, Inc. |
Engineered meganucleases having specificity for a recognition sequence in the hydroxyacid oxidase 1 gene
|
JP2024504614A
(ja)
|
2021-01-14 |
2024-02-01 |
トランスレイト バイオ, インコーポレイテッド |
mRNAがコードする抗体を送達する方法および組成物
|
EP4284823A1
(en)
|
2021-01-28 |
2023-12-06 |
Precision BioSciences, Inc. |
Modulation of tgf beta signaling in genetically-modified eukaryotic cells
|
CA3209779A1
(en)
|
2021-02-01 |
2022-08-04 |
Regenxbio Inc. |
Gene therapy for neuronal ceroid lipofuscinoses
|
CA3207791A1
(en)
|
2021-02-09 |
2022-08-18 |
Shanghai Junshi Biosciences Co., Ltd. |
Anti-cd112r antibody and use thereof
|
WO2022177597A1
(en)
*
|
2021-02-16 |
2022-08-25 |
The Board Of Trustees Of The Leland Stanford Junior University |
Systems and methods to enhance rna stability and translation and uses thereof
|
KR20230150319A
(ko)
|
2021-03-01 |
2023-10-30 |
사이롬 게임베하 |
iRhom2에 대한 인간화 항체
|
US20220323553A1
(en)
*
|
2021-03-08 |
2022-10-13 |
The Trustees Of The University Of Pennsylvania |
Epigenomic editing and reactivation of targets for the treatment of Fragile X syndrome
|
WO2022204549A1
(en)
|
2021-03-25 |
2022-09-29 |
Translate Bio, Inc. |
Optimized nucleotide sequences encoding the extracellular domain of human ace2 protein or a portion thereof
|
WO2022207652A1
(en)
|
2021-03-29 |
2022-10-06 |
Scirhom Gmbh |
Methods of treatment using protein binders to irhom2 epitopes
|
WO2022214664A1
(en)
|
2021-04-09 |
2022-10-13 |
Philogen S.P.A. |
Improved interferon-gamma mutant
|
JP2024515668A
(ja)
|
2021-04-19 |
2024-04-10 |
トランスレイト バイオ, インコーポレイテッド |
Mrnaの送達のための改善された組成物
|
EP4326861A1
(en)
|
2021-04-22 |
2024-02-28 |
Precision Biosciences, Inc. |
Engineered meganucleases that target human mitochondrial genomes
|
EP4326862A1
(en)
|
2021-04-22 |
2024-02-28 |
Precision Biosciences, Inc. |
Engineered meganucleases that target human mitochondrial genomes
|
CN117222749A
(zh)
|
2021-04-29 |
2023-12-12 |
翻译生物公司 |
用于测量聚a尾长度的方法
|
CN117396604A
(zh)
*
|
2021-04-30 |
2024-01-12 |
宾夕法尼亚大学理事会 |
用于将脂质纳米颗粒疗法靶向干细胞的组合物和方法
|
US11639501B2
(en)
|
2021-05-07 |
2023-05-02 |
Helix Nanotechnologies, Inc. |
Modified ribonucleic acids and uses thereof
|
WO2022234003A1
(en)
|
2021-05-07 |
2022-11-10 |
Avacta Life Sciences Limited |
Cd33 binding polypeptides with stefin a protein
|
EP4351623A1
(en)
|
2021-06-09 |
2024-04-17 |
Icahn School of Medicine at Mount Sinai |
Gene combination as a broad spectrum antiviral
|
AU2022301302A1
(en)
|
2021-07-01 |
2024-01-25 |
Indapta Therapeutics, Inc. |
Engineered natural killer (nk) cells and related methods
|
WO2023278754A1
(en)
|
2021-07-01 |
2023-01-05 |
Translate Bio, Inc. |
Compositions for delivery of mrna
|
EP4377459A2
(en)
|
2021-07-30 |
2024-06-05 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of frataxin (fxn)
|
WO2023010135A1
(en)
|
2021-07-30 |
2023-02-02 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
|
EP4388090A1
(en)
|
2021-08-16 |
2024-06-26 |
Translate Bio, Inc. |
Screening codon-optimized nucleotide sequences
|
WO2023025303A1
(zh)
|
2021-08-26 |
2023-03-02 |
上海君实生物医药科技股份有限公司 |
抗cldn-18.2抗体药物偶联物及其用途
|
TW202334196A
(zh)
|
2021-10-07 |
2023-09-01 |
英商阿法克塔生命科學有限公司 |
Pd-l1結合多肽
|
WO2023057946A1
(en)
|
2021-10-07 |
2023-04-13 |
Avacta Life Sciences Limited |
Serum half-life extended pd-l1 binding polypeptides
|
AU2022371430A1
(en)
|
2021-10-19 |
2024-05-30 |
Precision Biosciences, Inc. |
Gene editing methods for treating alpha-1 antitrypsin (aat) deficiency
|
AU2022368911A1
(en)
|
2021-10-19 |
2024-05-30 |
Precision Biosciences, Inc. |
Gene editing methods for treating alpha-1 antitrypsin (aat) deficiency
|
WO2023068931A1
(en)
|
2021-10-21 |
2023-04-27 |
Curevac Netherlands B.V. |
Cancer neoantigens
|
EP4186528A1
(en)
|
2021-11-30 |
2023-05-31 |
BioNTech SE |
Oligosaccharide complexes and uses
|
AU2022369405A1
(en)
|
2021-10-22 |
2024-05-09 |
BioNTech SE |
Oligosaccharide compounds and complexes
|
EP4169579A1
(en)
|
2021-10-22 |
2023-04-26 |
BioNTech SE |
Disulfide oligosaccharide compounds and complexes
|
EP4286004A1
(en)
|
2022-05-30 |
2023-12-06 |
BioNTech SE |
Disulfide oligosaccharide compounds and complexes
|
WO2023067123A1
(en)
|
2021-10-22 |
2023-04-27 |
BioNTech SE |
Oligosaccharide complexes and uses
|
EP4286394A1
(en)
|
2022-05-30 |
2023-12-06 |
BioNTech SE |
Oligosaccharide compounds and complexes
|
WO2023067125A1
(en)
|
2021-10-22 |
2023-04-27 |
BioNTech SE |
Oligosaccharide complexes and uses
|
EP4286003A1
(en)
|
2022-05-30 |
2023-12-06 |
BioNTech SE |
Oligosaccharide compounds and complexes
|
EP4285932A1
(en)
|
2022-05-30 |
2023-12-06 |
BioNTech SE |
Oligosaccharide complexes and uses
|
WO2023067126A1
(en)
|
2021-10-22 |
2023-04-27 |
BioNTech SE |
Oligosaccharide compounds and complexes
|
WO2023067124A1
(en)
|
2021-10-22 |
2023-04-27 |
BioNTech SE |
Disulfide oligosaccharide compounds and complexes
|
EP4169580A1
(en)
|
2021-10-22 |
2023-04-26 |
BioNTech SE |
Oligosaccharide compounds and complexes
|
EP4285933A1
(en)
|
2022-05-30 |
2023-12-06 |
BioNTech SE |
Oligosaccharide complexes and uses
|
EP4169578A1
(en)
|
2021-10-22 |
2023-04-26 |
BioNTech SE |
Oligosaccharide compounds and complexes
|
EP4169534A1
(en)
|
2021-10-22 |
2023-04-26 |
BioNTech SE |
Oligosaccharide complexes and uses
|
WO2023081767A1
(en)
|
2021-11-05 |
2023-05-11 |
Precision Biosciences, Inc. |
Methods for immunotherapy
|
WO2023083434A1
(en)
*
|
2021-11-09 |
2023-05-19 |
BioNTech SE |
Rna encoding peptidoglycan hydrolase and use thereof for treating bacterial infection
|
WO2023086893A1
(en)
|
2021-11-10 |
2023-05-19 |
Translate Bio, Inc. |
Composition and methods for treatment of primary ciliary dyskinesia
|
WO2023107954A1
(en)
|
2021-12-08 |
2023-06-15 |
Dragonfly Therapeutics, Inc. |
Antibodies targeting 5t4 and uses thereof
|
EP4202045A1
(en)
|
2021-12-22 |
2023-06-28 |
Universität Hamburg |
Synthetic transfer rna with modified nucleotides
|
TW202346348A
(zh)
|
2022-01-10 |
2023-12-01 |
美商再生元醫藥公司 |
作為基因治療所遞送之bbb靶向的gaa在龐貝氏症小鼠模型中治療cns及肌肉
|
WO2023183921A2
(en)
|
2022-03-24 |
2023-09-28 |
Nature's Toolbox, Inc. |
Methods and compositions for the enzymatic production of pseudouridine triphosphate
|
WO2023218243A1
(en)
|
2022-05-12 |
2023-11-16 |
Avacta Life Sciences Limited |
Lag-3/pd-l1 binding fusion proteins
|
WO2023232747A1
(en)
|
2022-05-30 |
2023-12-07 |
BioNTech SE |
Complexes for delivery of nucleic acids
|
WO2023240074A1
(en)
|
2022-06-07 |
2023-12-14 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of pcsk9
|
EP4314267A1
(en)
|
2022-06-07 |
2024-02-07 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of pcsk9
|
WO2023250511A2
(en)
|
2022-06-24 |
2023-12-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression
|
US11878055B1
(en)
|
2022-06-26 |
2024-01-23 |
BioNTech SE |
Coronavirus vaccine
|
WO2024007020A1
(en)
|
2022-06-30 |
2024-01-04 |
Indapta Therapeutics, Inc. |
Combination of engineered natural killer (nk) cells and antibody therapy and related methods
|
US20240100188A1
(en)
|
2022-07-11 |
2024-03-28 |
Icahn School Of Medicine At Mount Sinai |
Regulatory system for expression of a gene of interest in a target cell and method of use thereof
|
WO2024015881A2
(en)
|
2022-07-12 |
2024-01-18 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for targeted transcriptional activation
|
WO2024023246A1
(en)
|
2022-07-28 |
2024-02-01 |
Philogen S.P.A. |
Antibody binding to pd1
|
WO2024033362A1
(en)
|
2022-08-08 |
2024-02-15 |
Atb Therapeutics |
Humanized antibodies against cd79b
|
WO2024040254A2
(en)
|
2022-08-19 |
2024-02-22 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression
|
AU2023274159A1
(en)
|
2022-09-07 |
2024-03-21 |
Eyegene Inc. |
COMPOSITION FOR IN-VIVO DELIVERING mRNA CONTAINING MODIFIED NUCLEOTIDE
|
WO2024064642A2
(en)
|
2022-09-19 |
2024-03-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for modulating t cell function
|
WO2024064732A2
(en)
|
2022-09-20 |
2024-03-28 |
Visterra, Inc. |
Treatment of complement mediated diseases and disorders with c3b-antibodies
|
WO2024068674A1
(en)
|
2022-09-26 |
2024-04-04 |
BioNTech SE |
Nucleic acid complexes and uses thereof
|
WO2024086827A2
(en)
|
2022-10-20 |
2024-04-25 |
Repertoire Immune Medicines, Inc. |
Cd8 t cell targeted il2
|
WO2024084462A1
(en)
|
2022-10-21 |
2024-04-25 |
BioNTech SE |
Nucleic acid complexes and uses thereof
|
WO2024112652A1
(en)
|
2022-11-21 |
2024-05-30 |
Translate Bio, Inc. |
Compositions of dry powder formulations of messenger rna and methods of use thereof
|
WO2024126809A1
(en)
|
2022-12-15 |
2024-06-20 |
Sanofi |
Mrna encoding influenza virus-like particle
|
WO2024133515A1
(en)
|
2022-12-20 |
2024-06-27 |
Sanofi |
Rhinovirus mrna vaccine
|
WO2024133884A2
(en)
|
2022-12-23 |
2024-06-27 |
Sanofi |
Optimized tailing of messenger rna
|